RxDoctor Payments Data

Propa Ghosh, MD

Urology · Hamilton, NJNPI 1659601102

Payments from drug & device makers

$4,743in general payments, 2019–2025

Across 208 payments — averaging $22.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$1K
  • Sumitomo Pharma America, Inc.$389
  • Astellas Pharma US Inc$332
  • Procept Biorobotics Corporation$262
  • Dendreon Pharmaceuticals LLC$249
  • Antares Pharma, Inc.$215
  • plus $2K from 36 others
$533in research payments, 2019–2025

Across 1 payment — averaging $532.50 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Medtronic$533

What the payments were for

  • Food & beverage$4,50095%
  • Education$2435%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,743 in reported general payments places this provider in the 65th percentile of 401 urology providers in New Jersey.

See all urology providers in New Jersey

Medicare billing

Part B allowed, 2024
$268,238
Medicare patients
539
Services billed
3,769

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
GemtesaVibegron194$175,304
Estradiol480$71,857
MyrbetriqMirabegron69$52,745
YuvafemEstradiol129$22,221
EstringEstradiol40$20,437
Solifenacin Succinate232$17,750
Silodosin150$13,327
Tamsulosin Hcl450$6,701
Methenamine Hippurate53$5,779
Finasteride324$5,104
Tadalafil57$4,712
Oxybutynin Chloride ErOxybutynin Chloride63$2,300
Oxybutynin Chloride162$1,501
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst33$1,350
Trimethoprim13$779

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Sumitomo Pharma America, Inc.Gemtesa$389$175,304194 claims
Astellas Pharma US IncMyrbetriq$332$52,74569 claims
PfizerEstring$143$20,43740 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 401 urology providers in New Jersey.

Other urology in Hamilton

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →